Sinarmas Healthcare

PreferUS’ longevity and unique service offerings in the China healthcare market have attracted many international companies that have a strong interest in exploring the China market. In August of 2018, Sinar Mas Group, one of the largest conglomerates in Indonesia, and PreferUS entered into an equity partnership to pursue healthcare and hospital opportunities in China under the Sinarmas Healthcare brand.

As an important strategic investor, Sinarmas Healthcare, is focused on collaborating with PreferUS to identify and secure partnerships with hospitals that are highly reputable but still in need of advancing their services to the next level. In August of 2008, as part of Sinar Mas’ “initiative projects” the group established the EKA Hospital system in Jakarta consisting of two locations with a total of 500 beds. Annually, EKA Hospital cares for an average of 500,000 patients and completes 6,000 surgical procedures while managing over 60,000 medical follow ups.  

Sinar Mas has already established themselves throughout China with several businesses including: Pulp & Paper production, Developer & Real Estate, Financial Services and Agriculture & Food Processing. In May of 2004, Sinar Mas Group ranked second in foreign-invested companies on the “China Philanthropy List” of Forbes Chinese due to its outstanding contributions to the charitable undertaking of China. Their presence in the Indonesian healthcare market is very strong with two new profitable and highly reputable hospitals and two more hospitals opening soon. 

Sinar Mas’ success in China with their respective industries and healthcare expertise in Indonesia combined with PreferUS’ ten years of experience in China’s healthcare environment will help in creating a platform for both entities to work together in providing the best medical management services to the China market. As a key differentiator to the PreferUS brand, the partnership with Sinar Mas brings a new perspective to the mission and has now firmly positioned PreferUS for success.